Accent Therapeutics to Highlight Preclinical Data of ATX-559 and ATX-295 at AACR 2025
Shots:
- Accent Therapeutics to present preclinical data of ATX-559 (DHX9 inhibitor) & ATX-295 (KIF18A inhibitor) at AACR 2025
- Presentation will highlight ATX-559’s activity in cancers exhibiting genomic instability & replication stress in in vivo models, incl. dMMR/MSI-H colorectal & BRCA-altered triple-negative breast cancer, plus ATX-295’s activity in ovarian cancer & its relation with whole genome doubling as a sensitivity biomarker
- ATX-559 is being evaluated in P-I/II dose-escalation and expansion trial for advanced or metastatic BRCA-1 and/or BRCA-2-deficient breast cancer or MSI-H and/or dMMR solid tumors while ATX-295 is expected to enter clinical stage in H1’25
Ref: Prnewswire | Image: Accent Therapeutics
Related News:- Accent Therapeutics Receives the US FDA’s IND Approval of ATX-559 for Treating Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com